Joseph L Pater
Overview
Explore the profile of Joseph L Pater including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
28
Citations
1436
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Everest L, Blommaert S, Tu D, Pater J, Hay A, Cheung M, et al.
Value Health
. 2022 Jul;
25(7):1157-1164.
PMID: 35779942
Objectives: The development of novel cancer therapies, including immuno-oncology agents, has increased interest in reconstructed individual patient data (IPD) based restricted mean survival time (RMST) analyses. Additionally, reconstructed IPD-based RMST...
2.
Hay A, Mittmann N, Crump M, Cheung M, Sleeth J, Needham J, et al.
Curr Oncol
. 2021 Apr;
28(2):1153-1160.
PMID: 33800281
In a prospective study, we sought to determine acceptability of linkage of administrative and clinical trial data among Canadian patients and Research Ethics Boards (REBs). The goal is to develop...
3.
Del Paggio J, Fundytus A, Hopman W, Pater J, Chen B, Brundage M, et al.
J Natl Cancer Inst
. 2021 Mar;
113(10):1422-1428.
PMID: 33760057
Background: Use of value framework thresholds in the design of clinical trials may increase the proportion of randomized controlled trials that identify clinically meaningful advances for patients. Existing frameworks have...
4.
Monteith B, Venner C, Reece D, Kew A, Lalancette M, Garland J, et al.
Clin Lymphoma Myeloma Leuk
. 2020 Aug;
20(11):e791-e800.
PMID: 32807717
Thrombotic microangiopathy (TMA) is a life-threatening clinical syndrome characterized by hemolytic anemia, thrombocytopenia, and microvascular thrombosis, resulting in ischemia and organ damage. Multiple myeloma (MM) is a neoplasm arising from...
5.
Hay A, Pater J, Corn E, Han L, Camacho X, OCallaghan C, et al.
Clin Trials
. 2018 Nov;
16(1):14-17.
PMID: 30466310
Background: Clinical trials are important but extremely costly. Utilization of routinely collected administrative data may simplify and enhance clinical trial data collection. Purpose: The aim of this study was to...
6.
Duffin J, Pater J
Can Bull Med Hist
. 2018 Oct;
35(2):413-436.
PMID: 30365373
In 1962, Pete Seeger recorded "The Ballad of Doctor Dearjohn" about Canadian Medicare and the Saskatchewan doctors' strike of the same year. How had this New Yorker, recently relieved of...
7.
Duffin J, Pater J
Can Bull Med Hist
. 2018 Oct;
:1-24.
PMID: 30274527
In 1962, Pete Seeger recorded "The Ballad of Doctor Dearjohn" about Canadian Medicare and the Saskatchewan doctors' strike of the same year. How had this New Yorker, recently relieved of...
8.
Monzon J, Hay A, McDonald G, Pater J, Meyer R, Chen E, et al.
Eur J Cancer
. 2015 Sep;
51(17):2501-7.
PMID: 26338195
Background And Aim: The primary aim of this study was to determine whether randomised phase 2 (RP2) trials predict phase 3 trial outcome better than single arm phase 2 (SAP2)...
9.
Maunsell E, Goss P, Chlebowski R, Ingle J, Ales-Martinez J, Sarto G, et al.
J Clin Oncol
. 2014 Apr;
32(14):1427-36.
PMID: 24711552
Purpose: Exemestane, a steroidal aromatase inhibitor, reduced invasive breast cancer incidence by 65% among 4,560 postmenopausal women randomly assigned to exemestane (25 mg per day) compared with placebo in the...
10.
Pater J, Goss P, Meyer R
J Clin Oncol
. 2008 May;
26(16):2787-8.
PMID: 18509191
No abstract available.